Emmaus Life SciencesEMMA -16.67% FCF Yield % is -90.31 as of Jun. 26, 2026. The stock has 6 warning signs investors should review. Among 1,418 Biotechnology companies, Emmaus Life Sciences ranks worse than 87.59% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Emmaus Life Sciences FCF Yield % Related Terms
Emmaus Life Sciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a FCF Yield % of -90.31 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #1242 out of 1418 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Emmaus Life Sciences' FCF Yield % too high?
Emmaus Life Sciences' current FCF Yield % is -90.31. Based on the distribution chart, Emmaus Life Sciences ranks #1242 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' FCF Yield % compare to CERO and AGTX?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #1242 out of 1418 companies for FCF Yield %. This places Emmaus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current FCF Yield % is -90.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current FCF Yield % is -90.31. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current FCF Yield % is -90.31 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 